General Terms & Conditions governing the use of funding provided by Amicus Therapeutics UK Limited (“Amicus”) (“Terms”) through Amicus Ignite.
Version: January 2025.
These Terms apply to funding awarded through the Amicus Ignite programme (“Funding”). Funding is provided to successful applications following submission of proposals to the Amicus Ignite application and evaluation process. Funding will only be provided when a full funding agreement has been signed by the Funding Recipient and Amicus Therapeutics UK Limited incorporating these Terms among other matters (“Funding Agreement”).
Note: Funding cannot be provided to organisations registered in the United States or for projects located in the US.
Amendments to Project Scope and Budget – Amicus will not provide any additional funding to support a project that has been awarded Funding through the Amicus Ignite programme. If it becomes apparent that the relevant project cannot be completed or that additional funding will be required in order to support project completion, the Funding Recipient must contact Amicus as soon as possible.
Financial Reporting – Within three (3) months of the completion of the project, the Funding Recipient shall deliver to Amicus a breakdown on how the Funding has been used for the purpose of the relevant project. Upon request from Amicus, the Funding Recipient will provide Amicus with all documentation to support the use of the Funding for the purpose of the project.
Funding / Funding Award – The Funding will only be paid to Funding Recipient named in the application submitted to Amicus. In the event that the Funding Recipient is unable to accept payment from Amicus Therapeutics UK Limited, Amicus reserves the right to withdraw the Funding award and to fund an alternative organisation the funding if appropriate.
Funding Period – The Funding must be used within the period set out in the Funding Agreement.
Funding Recipient – A healthcare institution, patient advocacy organisation, academic institution, or charitable organisation in whose name the application has been submitted and such application is successful.
Governing Law & Jurisdiction – These Terms and the Funding Agreement shall be interpreted and governed in accordance with English law and the courts of England and Wales shall have exclusive jurisdiction in relation to any disputes.
Payment of Funding – In accordance with the Funding Agreement, Amicus may pay the Funding to the Funding Recipient in a lump sum or at specific times according to deliverables. The Funding Recipient will be responsible for the payment of all taxes associated with receipt of the Funding. Amicus shall have no responsibility in this regard. Funding of up to €20,000 (or local currency equivalent) for a limited number of projects is available.
Project Delay – The Funding Recipient must immediately notify Amicus if: (i) there is a material delay to the Project; or (ii) if the Funding Recipient considers that a delay is likely to occur; (iii) there is any change in any assumptions that are a material part of the Project. In addition to the notification, the Funding Recipient must also include information about project risks and how these risks can be mitigated. Amicus will consider all relevant information in order to determine whether it will continue to pay the Funding or request return of any unused portion of the Funding.
Project Reporting – Subject to local regulations, the Funding Recipient will provide Amicus with a project update half way through the project summarising the project status, current and projected outcomes. Within three (3) months of completion of the project, the Funding Recipient will provide Amicus with a final report setting out the main results of the project, learnings and conclusions. In accordance with local laws and regulations, and the terms of the Funding Agreement, Amicus Ignite will publish the submitted final reports on the Amicus Ignite website. In some cases local laws and regulations concerning transparency and disclosure may require Amicus to report Funding to third parties.
Publication – The Funding Recipient agrees that it will use its best efforts to publish the results, conclusions and learnings from the project in order that others may benefit from the project in the furtherance of patient care. When the Funding Recipient publishes the results of the project, the funding provided by Amicus Ignite must be acknowledged using the following form of words: “This project was supported by funding from Amicus Therapeutics UK Limited as part of the Amicus Ignite funding project which aims to support projects that enable better patient outcomes.”
Publicity – Amicus will make public information about the award of funding through the Amicus Ignite programme. This will include a listing of the Funding Recipient’s name and logo, in the form provided to Amicus as well as an overview of the project and its status.
Transparency Reporting – The Funding Recipient acknowledges that Amicus may be required to report the provision of the Funding pursuant to laws and industry codes of practice relating to the transfers of value.
Use of Funding – Funding may only be used for the purpose of completing the project described in the Funding Recipient’s proposal. It may not be used for any other purpose. In the event that the Funding has been used for an alternative purpose, Amicus reserves the right to recover the full Funding amount from the Funding Recipient.
Unused Funding – If the Funding Recipient completes the relevant project without spending all of the Funding, the Funding Recipient will return to Amicus any unused portion of the Funding. Unused portions must be returned to Amicus within three (3) months.
